The Man Behind the Trump Administration’s Favorite Psychedelic

W. Bryan Hubbard’s journey from conservative lawyer to psychedelic advocate has left many in the industry wondering what sparked his conversion and how he managed to persuade some of the most unlikely individuals, including Donald Trump, to take notice of ibogaine.

Hubbard’s story is a reflection of the changing landscape of psychedelics politics. For decades, the left has been associated with psychedelic advocacy, from the 1960s counterculture to modern-day efforts to decriminalize substances like psilocybin and MDMA. However, Hubbard’s success in tapping into Republican enthusiasm for ibogaine marks a significant shift.

Hubbard’s personal transformation is key to understanding his influence. A self-described “typical conservative” who once viewed psychedelics as “subversive” and “harmful,” he had an epiphany after reading about psilocybin research on alcohol-use disorder. His subsequent experiences with the substance, coupled with exposure to advocacy efforts, led him to reevaluate his stance.

Hubbard notes that he has found more success proselytizing for ibogaine among conservative Republicans than among liberals. This might be due in part to the fact that many on the right are now open to exploring unconventional solutions to problems like opioid addiction. Trump’s executive order accelerating research on psychedelics, including ibogaine, is a testament to this shift.

The involvement of figures like Rick Perry and Donald Trump themselves speaks to a broader pattern of mainstreaming psychedelics in Washington. While some might view Hubbard’s efforts as a cynical attempt to co-opt psychedelic enthusiasm for Republican ends, it’s equally possible that he has genuinely found a way to bridge the ideological divide.

Hubbard’s success highlights the need for a more nuanced understanding of the politics surrounding psychedelics. As research on these substances continues to evolve, so too must our assumptions about who is likely to be sympathetic to their potential benefits.

Ibogaine has long been touted as a “miracle cure” for opioid addiction, with its use in traditional Gabonese rituals and scattered reports of efficacy in treating withdrawal symptoms and cravings. Despite these claims, ibogaine’s scientific record remains spotty at best, with only a handful of preclinical studies and a single Phase 1 trial under its belt.

Despite the lack of concrete evidence, Hubbard and others like him remain undeterred in their advocacy for ibogaine. They argue that the compound holds endless promise, particularly in addressing opioid addiction. However, critics point out that the scientific record is far from established, raising concerns about the legitimacy of ibogaine as a medical treatment.

Advocacy groups have long played a crucial role in pushing psychedelic research forward. From Howard Lotsof’s early efforts to raise awareness about ibogaine’s potential benefits for opioid addiction to the current wave of Substack writers and social media influencers, grassroots activism has been instrumental in keeping psychedelics on the radar.

However, Hubbard’s experience shows that even the most unlikely individuals can be won over with persistence and a compelling message. His success raises questions about the boundaries between advocacy and lobbying – and whether the latter is truly a new era of influence in Washington or simply a continuation of existing patterns.

As ibogaine becomes increasingly linked to high-profile efforts to address opioid addiction, it’s clear that psychedelic enthusiasm has reached a tipping point. Trump’s executive order represents a significant milestone in the mainstreaming of psychedelics.

The implications are far-reaching. If Republicans like Hubbard can successfully tap into this new era of acceptance, it could signal a sea change in the way policymakers approach substance use and addiction treatment. However, there are also risks – not least the potential for co-optation or exploitation by those who would seek to harness psychedelic enthusiasm for their own ends.

As Hubbard looks out on a new landscape of psychedelics politics, what does the future hold? Will his efforts continue to bear fruit, paving the way for even more unlikely alliances and breakthroughs? Or will the complex web of interests and agendas that has come to define psychedelic advocacy ultimately prove too daunting to navigate?

One thing is certain: Hubbard’s remarkable journey marks only the beginning of a new era in psychedelics politics – one that will require agility, adaptability, and a willingness to challenge assumptions about what it means to be part of this complex and ever-shifting landscape.